CAMBRIDGE, Mass.--()--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, announced today that it has been selected to deliver the keynote address on Targeting of Nanoparticles at the American Society of Mechanical Engineers (ASME) 2013 Global Congress on Nanoengineering for Medicine and Biology (NEMB) taking place February 4-6, 2003, in Boston, MA.
In his keynote address on targeted nanomedicines, Jeff Hrkach, Ph.D., BIND’s Sr. Vice President of Technology, Research and Development, will discuss the significant advances being made in the development of nanoparticle-based therapeutics including sophisticated capabilities to target diseased tissues for optimized therapeutic benefit. By unlocking the targeting potential of nanoparticles, major advances in drug development, including cancer treatments are now being realized. To illustrate these advances, Dr. Hrkach will present BIND’s Medicinal Nanoengineering® platform as a case study. BIND’s platform creates Accurins with optimal targeting and drug release properties. BIND’s most advanced Accurin, BIND-014, is showing promising results in human clinical testing in patients with solid tumor cancers.
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Medicinal Nanoengineering® platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead product candidate, BIND-014, is currently in Phase 1 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.